price oct usd
investor question whether organ growth miss harbing
given play extrem divers array end market global
fairli broad list reason compani organ growth came
weaker manag expect entir surpris
investor question whether view neg read
broad econom growth especi sinc come day also
deliv line market expect listen call
speak manag convinc time panic
seem face sever company-spec issu drove quarter
under-perform view broad-bas growth problem
erp implement repres headwind us growth
impli underli growth strong compani cover
 broadli line ip growth automot a/m declin
revenu lsd organ basi particularli surpris given
recent commentari drug deliveri declin busi
lumpi natur y/i tough comp pipelin
suggest stabil roof granul declin revenu
mid-teen shingl manufactur slow product comp tough
 hurrican could drive pickup
said prefer compani later-cycl industri exposur due
stronger organ growth outlook
believ weaker expect organ growth rais
major global growth red ag also think within compani growth
like constrain rel compani cover
greater late-cycl end market exposur big part compani
exposur global auto oem vertic also dicult time call
materi step-up demand within consum industri vs
trend model organ growth well expect
like honeywel emerson ep forecast
fall vs prior toward high end new guidanc
reduc pt maintain hold rate
cut number price target fall base
ntm price-to-earnings given modest upsid vs current share price maintain
hold rate risk upsid outsiz progress cost cut initi
subsequ margin improv acceler organ growth downsid
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
increas headwind fx price/cost increas intern invest well
exogen factor econom downturn geopolit instabl
forecast ratio
segment y/ydb varvar organ growth fx divestitur growth sub-seg auto oem vs global car lt truck build auto a/m declin lsd organ adhes tape busi lsd advanc materi dd geographi apac us latam/canada emea organ growth fx acquisit safeti comp organ transport safeti grew msd commerci solut lsd roof granul declin mid-teen geographioc apac led organ growth us latam/canada emea organ vs organ comp driven continu softwar drug deliveri busi depend pharmaceut regulatori time line custom budget fx drug deliveri organ oral organ medic solut declin slightli geograph asiapac led way growth latam/canada emea us organ fx divestitur electron grew organ geograph us led growth apac latam/canada emea organ declin fx improv grew lsd organ vs busi saw y/i declin geographi us apac latam/canada emea incom oper margin margin margin margin margin margin increment increment increment increment benefit mix divestitur commun market increment increment octob
incom statement y/ydb varvar commentsnet organ acquisit fx manag expect fy organ growth sale us declin y/i part due erp implement global revenu new erp system manag expect lesser impact latam/canada emea apac good y/i due impact drug deliveri busi higher d/sale ratio compani averag sale businesses- n/a- oper volum product lower y/i portfolio footprint action ad margin sell price benefit off-set raw materi inflat ad net margin headwind fx impact acquisit primarili scott safeti headwind divestitur commun market businessexcept items- n/a- oper expens incom tax rate driven us tax reform fy guidanc net ops- n/a- net incom attribut n/a- net share spent repurchas expect spend full yearheadlin updat guidanc fy ep adj bs/cf y/ydb manag expect fy capital-expenditure expect fy convers octob
compani guidancecurrentpriortot revenu local currenc growth segment health half fund repurchas incom
ye decemb y/i organ profit gain sale report oper incom oper incom ebit expens pre-tax incom effect incom disc ops- gaap net incom incom attribut non-control gaap net incom attribut adjustments- headlin incom share headlin ep y/i ep
ye decemb net depreci chang trade work oper proce sale invest equiti stock debt financ increase/ decreas end balanc oper proce sale free octob
